Why use long-term macrolide therapy in pediatric pulmonology?;Pourquoi utiliser les macrolides au long cours en pneumologie pédiatrique?

Archives de Pediatrie

Volumn 21, Issue 3, 2014, Pages 314-321

  Corvol, H ^a   Taytard, J ^a   Thouvenin, G ^a   Perisson C ^a   Nathan, N ^a   Clement, A ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE;

ASTHMA; BRONCHIECTASIS; CYSTIC FIBROSIS; HUMAN; LONG TERM CARE; LUNG DISEASE; PEDIATRICS; PULMONOLOGY; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; MACROLIDES; TIME FACTORS;

EID: 84896724324     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2013.12.023     Document Type: Short Survey

References (54)

1. Itkin I.H., Menzel M.L. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970, 45:146-162.
2. Nelson H.S., Hamilos D.L., Corsello P.R., et al. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993, 147:398-404.
3. Zeiger R.S., Schatz M., Sperling W., et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 1980, 66:438-446.
4. Kudoh S. Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases. Am J Med 2004, 117(Suppl 9A):12S-19S.
5. Kudoh S., Azuma A., Yamamoto M., et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
6. Fujii T., Kadota J., Kawakami K., et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995, 50:1246-1252.
7. Kadota J., Mukae H., Ishii H., et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003, 97:844-850.
8. Parnham M.J. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18:125-131.
9. Guillot L., Tabary O., Nathan N., et al. Macrolides: new therapeutic perspectives in lung diseases. Int J Biochem Cell Biol 2011, 43:1241-1246.
10. Rubin B.K. Immunomodulatory properties of macrolides: overview and historical perspective. Am J Med 2004, 117(Suppl 9A):2S-4S.
11. Rubin B.K., Henke M.O. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 2004, 125:70S-78S.
12. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010, 23:590-615.
13. Desaki M., Okazaki H., Sunazuka T., et al. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother 2004, 48:1581-1585.
14. Clement A., Tamalet A., Leroux E., et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006, 61:895-902.
15. Equi A., Balfour-Lynn I.M., Bush A., et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
16. Rotschild M., Elias N., Berkowitz D., et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clin Exp Med 2005, 5:80-85.
17. Saiman L., Anstead M., Mayer-Hamblett N., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715.
18. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
19. Steinkamp G., Schmitt-Grohe S., Doring G., et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008, 102:1643-1653.
20. Wolter J., Seeney S., Bell S., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
21. Saiman L., Mayer-Hamblett N., Campbell P., et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005, 172:1008-1012.
22. Hansen C.R., Pressler T., Koch C., et al. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005, 4:35-40.
23. Pirzada O.M., McGaw J., Taylor C.J., et al. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibros 2003, 2:69-71.
24. Southern K.W., Barker P.M., Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004, CD002203.
25. Tramper-Stranders G.A., Wolfs T.F., Fleer A., et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007, 26:8-12.
26. Saiman L., Anstead M., Mayer-Hamblett N., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2011, 303:1707-1715.
27. Cai Y., Chai D., Wang R., et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011, 66:968-978.
28. Southern K.W. Macrolide antibiotics for cystic fibrosis. Paediatr Respir Rev 2012, 13:228-229.
29. Altenburg J., de Graaff C.S., Stienstra Y., et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
30. Cymbala A.A., Edmonds L.C., Bauer M.A., et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4:117-122.
31. Davies G., Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004, 59:540-541.
32. Serisier D.J., Martin M.L. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011, 105:946-949.
33. Serisier D.J., Martin M.L., McGuckin M.A., et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
34. Tsang K.W., Ho P.I., Chan K.N., et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13:361-364.
35. Wong C., Jayaram L., Karalus N., et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
36. Yalcin E., Kiper N., Ozcelik U., et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006, 31:49-55.
37. Koh Y.Y., Lee M.H., Sun Y.H., et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997, 10:994-999.
38. Richeldi L., Ferrara G., Fabbri L.M., et al. Macrolides for chronic asthma. Cochrane Database Syst Rev 2002, CD002997.
39. Richeldi L., Ferrara G., Fabbri L.M., et al. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005, CD002997.
40. Mikailov A., Kane I., Aronoff S.C., et al. Utility of adjunctive macrolide therapy in treatment of children with asthma: a systematic review and meta-analysis. J Asthma Allergy 2013, 6:23-29.
41. Reiter J., Demirel N., Mendy A., et al. Macrolides for the long-term management of asthma-a meta-analysis of randomized clinical trials. Allergy 2013, 68:1040-1049.
42. Piacentini G.L., Peroni D.G., Bodini A., et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007, 28:194-198.
43. Shimizu T., Kato M., Mochizuki H., et al. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994, 106:458-461.
44. Kamada A.K., Hill M.R., Ikle D.N., et al. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993, 91:873-882.
45. Eitches R.W., Rachelefsky G.S., Katz R.M., et al. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children. Am J Dis Child 1985, 139:264-268.
46. Flotte T.R., Loughlin G.M. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Pediatr Pulmonol 1991, 10:178-182.
47. Thouvenin G., Nathan N., Epaud R., et al. Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin. BMJ Case Rep 2013, 2013.
48. Van Bambeke F., Montenez J.P., Piret J., et al. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1activity. Eur J Pharmacol 1996, 314:203-214.
49. Kawai Y., Miyashita N., Kubo M., et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013, 57:4046-4049.
50. Jubin V., Ranque S., Stremler Le Bel N., et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010, 45:764-771.
51. Renna M., Schaffner C., Brown K., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2010, 121:3554-3563.
52. Tarran R., Sabater J.R., Clarke T.C., et al. Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. Am J Physiol Lung Cell Mol Physiol 2013, 304:L746-L756.
53. Kobayashi Y., Wada H., Rossios C., et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013, 169:1024-1034.
54. Kobayashi Y., Wada H., Rossios C., et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther 2013, 345:76-84.